Member Info for Malachi

That's a bit more to my liking. S Times punted it at the w/e

There was no obvious new reason why HZD should have fallen to ~110, or why it is now making a spirited recovery. possible overspending was not a new feasture. But it was a good buying opportunity, and the board members took it! So did I.

Yes, thanks, they are spending too much. A bad habit.

Why should this outfit, with excellent prospects and no bad news be tanking? Given the frequency of posts here, I may as well ask myself, but if there is anyone out there I would be interested to hear their views.

I think they may have worked on tailings to explain 29cpht?

This is extremely hairy. Is this just manipulation of an illiquid share or is there yet more bad news from SA that some know about and the rst of us PIs do not?

It is possible that ethics permission is easier in Germany than UK. I know UK ethics committees to be ponderous, and often ill informed about the subject matter, particularly on complex issues, and can take a nit picking approach where common sense is needed. Angle may have experienced this and once bitten..........

I am not convinced we will make any SP progress until FDA approval, which could be a long time.

Yes, that is it.

There is a lot of competition out there, both in USA and Europe, to use circulating DNA to determine the genetic profile of tumours. As far as I can see Parsortix differs in being able to isolate tumour cells with a high degree of success from which, of course, the DNA can be extracted. Others are looking for circulating DNA derived from tumour cells, but this cannot always be isolated from peripheral blood even in the presence of a known tumour. Two firms have already commercialised their techniques in the USA, but in each case they depend on the availability of circulating DNA. What Parsortix has to prove is that their recovery rate for circulating tumour cells is higher than the ability of competitors to isolate DNA from peripheral blood. I fear the FDA will be in no hurry to approve Parsortix if there was any competition for this technique in development in the US. There is a relevant article in Economist 11th June pp77-8.

Having read the Chemistry World article cited below I have a serious concern. Cronin is clearly a genius. as was said in the paper; 'Some of us eventually realised that this was someone who was overflowing with ideas and had little control over what he said.’ My concern is that he will always be thinking of the next idea, and will not stop to consider and develop the commercial aspects of his genius. There needs to be someone around him who can develop his ideas into commercial reality, while he charges on to the the next good idea. . There is no evidence of this at present, and no evidence that I have seen that any work for which he has the IP rights is presently heading towards commercialisation. I hope I am wrong.

Results, and the market response, confirm this post from almost 1 month ago. The statement if full of gobblydegook and bad english, but underlying this cr*p is a theme of lower revenues taking longer to achieve.

And 4 months after the last post we still have complete silence on what this crew are planning commercially. Scientists do not have a great record when it comes to commercialising their clever ideas.

This trial was based on small numbers, and a further much larger one is needed which will take ~18 months.Hence the muted response of teh SP FDA approval might take as long, assuming the trial confirms the findings of this small trial. The fact that they have been able to look at the metastatic RNA - different from the primary - is likely to be very important in determining treatment stategies. Parsortix is an absolute winner - but when?

The RNS makes clear that further (possibly multicentre) work needs to be done. This is time consuming, with the need for a new ethics application, which in my experience can be depressingly slow, and then enough time to get enough patients into the study to provide meaningful data. Hence the time frame of 18/12 before commercialisation is realistic, as I see it.

The patent is indeed good news, but I am less clear whether Parasortix has approval within the EU for sale for commercial use.

Come on FDA, finger out. When this passes their over prolonged scrutiny AGL will fly

I expect that these sales were to oncology centres with first class research records, and might not have been at full commercial cost, but relying on payback for Angle in terms of research output and publicity amongst the oncology community.

Eh?

Matters are hanging by a thread. As I understand the RNS,even if 6.5 M is raised, ZOX cannot move to making zinc oxide - which is much more profitable, until it has paid off the loans to Korea Zinc. Until then it has to supply zinc concentrate to KZ only. Even if the loans are paid, the kit required to make industrial grade zinc oxide, will cost 20 M and will take 18 months to get up and running. Until then we are tied to KZ at a presently uneconomic zinc price. I cannot see ZOX surviving that long. I fear my investment is a wipeout. [relevent RNS below.] The Directors estimate that a plant capable of upgrading 50% of KRP's zinc concentrate would cost about US$20 million and take one year to develop following six months pre-development work. The upgrading operation could, on certain assumptions* generate an additional US$11.7 million of EBITDA (zinc price of US$1,600 per tonne) per annum at plant level and reduce the break-even zinc price of the combined operations to about US$1,300 per tonne. The upgrading potential announced today could, therefore, have a significant medium term impact on the prospects for the Company. *assumptions include 1. 50% of the HZO is upgraded to commercial grade zinc oxide (IZO)(80% zinc contained). 2. Throughput at KRP of 200,000 tonnes of EAFD per annum and a recovery of 94%. 3. IZO will sell, net of operating costs at a premium of about 50% to the current off-take arrangements. 4. Lead and silver by product revenues of USD 1.7million, assuming a lead price of USD 1,440 / Tonne and Silver of USD 14 /Oz.